CNRS Enzyme and Cell Engineering Laboratory, Université de Technologie de Compiègne, Rue du Docteur Schweitzer, CS 60319, 60203, Compiègne Cedex, France.
Global CMC Early Development, Synthetics Platform, Sanofi-Aventis Deutschland GmbH, Industrial Park Hoechst, Building G849, 65926, Frankfurt/Main, Germany.
Angew Chem Int Ed Engl. 2023 Aug 21;62(34):e202306274. doi: 10.1002/anie.202306274. Epub 2023 Jul 11.
Tumor Necrosis Factor-α (TNF-α) is a cytokine that is normally produced by immune cells when fighting an infection. But, when too much TNF-α is produced as in autoimmune diseases, this leads to unwanted and persistent inflammation. Anti-TNF-α monoclonal antibodies have revolutionized the therapy of these disorders by blocking TNF-α and preventing its binding to TNF-α receptors, thus suppressing the inflammation. Herein, we propose an alternative in the form of molecularly imprinted polymer nanogels (MIP-NGs). MIP-NGs are synthetic antibodies obtained by nanomoulding the 3-dimensional shape and chemical functionalities of a desired target in a synthetic polymer. Using an in-house developed in silico rational approach, epitope peptides of TNF-α were generated and 'synthetic peptide antibodies' were prepared. The resultant MIP-NGs bind the template peptide and recombinant TNF-α with high affinity and selectivity, and can block the binding of TNF-α to its receptor. Consequently they were applied to neutralize pro-inflammatory TNF-α in the supernatant of human THP-1 macrophages, leading to a downregulation of the secretion of pro-inflammatory cytokines. Our results suggest that MIP-NGs, which are thermally and biochemically more stable and easier to manufacture than antibodies, and cost-effective, are very promising as next generation TNF-α inhibitors for the treatment of inflammatory diseases.
肿瘤坏死因子-α(TNF-α)是一种细胞因子,通常在免疫细胞对抗感染时产生。但是,在自身免疫性疾病中,当产生过多的 TNF-α时,会导致不必要的持续炎症。抗 TNF-α单克隆抗体通过阻断 TNF-α并防止其与 TNF-α受体结合,从而抑制炎症,从而彻底改变了这些疾病的治疗方法。在这里,我们提出了一种分子印迹聚合物纳米凝胶(MIP-NG)的替代方法。MIP-NG 是通过在合成聚合物中纳米成型所需靶标的三维形状和化学功能而获得的合成抗体。使用内部开发的计算合理方法,生成了 TNF-α的表位肽,并制备了“合成肽抗体”。所得的 MIP-NG 与模板肽和重组 TNF-α具有高亲和力和选择性的结合,并可以阻断 TNF-α与其受体的结合。因此,它们被应用于中和人 THP-1 巨噬细胞上清液中的促炎 TNF-α,从而下调促炎细胞因子的分泌。我们的结果表明,MIP-NG 比抗体在热和化学上更稳定,更容易制造,成本效益更高,作为下一代 TNF-α抑制剂用于治疗炎症性疾病非常有前途。